Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom Trial, Published in the Journal of the American Medical AssociationDaiichi Sankyo2020-08-03 09:26:30Bempedoic Acid Significantly Reduces LDL-Cholesterol on Top of Statin Therapy: Results of the CLEAR Wisdom
-
Pooled Analyses of Bempedoic Acid Phase 3 LDL-C Lowering Clinical Trial Programme to be Presented at the American Heart Association 2019 Scientific SessionsDaiichi Sankyo2020-08-03 09:28:15Pooled Analyses of Bempedoic Acid Phase 3 LDL-C Lowering Clinical Trial Programme to be Presented at the
-
European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly NVAF patients on LIXIANA®▼ (edoxaban)Daiichi Sankyo2020-08-03 09:30:42European results from Global ETNA-AF registry show low bleeding and low cardiovascular event rates in elderly
-
ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in Elderly NVAF PatientsDaiichi Sankyo2020-08-03 09:31:20ETNA-AF Registry Data Provide Real-world Evidence of the Efficacy and Safety Profile of LIXIANA® (edoxaban) in
-
Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol Lowering and Reduced hsCRP in Statin Intolerant PatientsDaiichi Sankyo2020-08-03 09:33:03Bempedoic Acid CLEAR Serenity Study Results Published in the JAHA Demonstrated Significant LDL-Cholesterol
-
Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter AblationDaiichi Sankyo2020-08-03 09:33:40Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral,
-
Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant LDL-cholesterol lowering and reduced marker of underlying cardiovascular inflammation, with a similar tolerability to placeboDaiichi Sankyo2020-08-03 09:34:15Bempedoic Acid Study 1 results published in The New England Journal of Medicine demonstrated significant
-
Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions at EHRA 2019, the Annual Congress of the European Heart Rhythm AssociationDaiichi Sankyo2020-08-03 09:35:00Daiichi Sankyo Announces New Data on Once-Daily LIXIANA®▼ (edoxaban) to be Presented in Late-Breaking Sessions
-
Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination TabletDaiichi Sankyo2020-08-03 09:35:39Daiichi Sankyo Europe and Esperion Announce Validation of the Marketing Authorisation Application (MAA) for
-
Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the Bempedoic Acid / Ezetimibe Combination TabletDaiichi Sankyo2020-08-03 09:36:09Daiichi Sankyo Europe Enters into European Licensing Agreement with Esperion for Bempedoic Acid and the
